ReviewJournal of translational medicine2026
Role and regulation of kinases in age-related macular degeneration.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- An In Vitro Evaluation of a New Approach in AMD: Effects of the Combination of Resveratrol and Anti-VEGFs on ARPE-19 Cells.Biomolecules · 2026Article
- A multimodal ocular aging index reveals proteomic pathways and predicts incident age-related eye diseases.npj aging · 2026Article
- Spontaneous whole retinal degeneration in aged Beclin1 heterozygous mice.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAge-related macular degeneration (AMD) is the leading cause of chronic blindness in the elderly and causes retinal pigment epithelium (RPE) and photoreceptor cells to degenerate and die. However, the specific pathogenic mechanism of AMD has yet to be explored. The development of new AMD therapeutics is urgently required. MAIN BODY: Studies have shown that kinases are increasingly important in AMD pathogenesis and treatment. Inhibition of apoptosis in retinal cells, such as RPE cells, maintenance of normal cellular metabolism, and preservation of normal autophagy are among the pathways involved in treating AMD. This is associated with kinase-related pathways, such as the PI3K/Akt, MAPK/ERK, JAK/STAT, mTOR, Ang-Tie, and AMPK signaling pathways.
conclusionsIn this review, we highlight recent advances in kinase-related pathways in treating AMD, to provide new directions for the prevention and treatment of AMD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.